Scinai Immunotherapeutics Ltd
SCNI
$3.41
Closing
▲0.29%
1D
▼-41.21%
YTD
SCNI
BBG007TGL3Q9
Market cap
$2.85M
52 week high
$13.15
52 week low
$2.34
Volume
267
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $6.99/month
Market cap
$2.85M
Analysts' Rating
-
Price Target (Mean)
700.00
Total Analysts
0
P/E
Operating Margin
-713.73%
Beta
2.52
Revenue Growth
0.00%
52 week high
$13.15
52 week low
$2.34
Div. Yield
%
EPS Growth
0.00
Company Profile
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company’s product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
